

Zoono Group Limited (ASX:ZNO) ASX ANNOUNCEMENT

28 August 2025

Shortfall Offer placement provides Zoono a further A\$992K in working capital

Zoono Group Limited (**Company**) (ASX: ZNO) is pleased to advise that, following on from its recent non-renounceable rights issue, it has today raised an additional \$992,000 by a placement of the remaining Shortfall Shares. This brings the total amount raised under the rights offer to \$1.78M (NZ\$1.95M), before costs.

The placement of 28,349,219 fully paid ordinary shares, issued at \$0.035 per share, was to investors associated with OSY Group Limited (**OSY**). OSY is a key driver of the shelf-life extension project (in conjunction with the Company) and, as such, the interest shown in the Company by OSY shareholders and their associates is pleasing.

In addition, the Company has agreed to issue up to 5,000,000 free shares (nil consideration) to Marc Braterman, CEO of OSY Group Limited, subject to attainment of the following conditions:

- 1,666,666 shares will be issued if gross sales of not less than NZ\$5 million are achieved into the shelf-life extension food packaging channel globally on or before 31 December 2026 (Tranche 1);
- A further 1,666,666 shares will be issued if gross sales of not less than NZ\$10 million are achieved into the shelf-life extension food packaging channel globally in the year ending 31 December 2027 or, alternatively, if gross sales of not less than \$15 million are achieved prior to 31 December 2027 (Tranche 2), you will be issued 3,333,332 shares less any shares previously issued under Tranche 1; and
- A further 1,666,666 shares will be issued if gross sales of not less than NZ\$15 million are achieved into the shelf-life extension food packaging channel globally in the year ending 31 December 2028 or, alternatively, if gross sales of not less than \$30 million are achieved prior to 31 December 2028 (Tranche 3), you will be issued 5,000,000 shares less any shares previously issued under Tranches 1 and 2.

The additional funds raised and incentive targets in place will help accelerate the Company's program to deliver its world-leading shelf-life extension technology for food producers, distributors and supermarket chains as well as the Company's marketing efforts in China, India, Korea, and Japan.

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop Group MD

M: +64 21 659 977

E: paul.hyslop@zoono.com

Paul Ravlich Group CFO

M: +64 21 075 9176

E: paul.ravlich@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com